{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:54:34Z","timestamp":1793840074719,"version":"4.6.1"},"reference-count":188,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH372"],"award-info":[{"award-number":["ZR2022QH372"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.heliyon.2023.e21776","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:20:30Z","timestamp":1699316430000},"page":"e21776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["CAR-T cell therapy for hematological malignancies: History, status and promise"],"prefix":"10.1016","volume":"9","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusheng","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2921-8866","authenticated-orcid":false,"given":"Hai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e21776_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e21776_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2023.e21776_bib3","doi-asserted-by":"crossref","DOI":"10.2478\/ahp-2020-0002","article-title":"A brief history of car-t cells: from laboratory to the bedside","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib4","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2023.e21776_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib6","article-title":"Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed\/refractory large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib8","article-title":"The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an e aaaaconomic evaluation of the ZUMA-7 trial","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.heliyon.2023.e21776_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7526","article-title":"Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy","author":"Nastoupil","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7526","article-title":"Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib12","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysi","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e21776_bib13","doi-asserted-by":"crossref","DOI":"10.1089\/clinomi.04.05.09","article-title":"Kymriah, first CAR-T cancer immunotherapy approved by FDA","volume":"4","author":"Philippidis","year":"2017","journal-title":"Clinical OMICs"},{"key":"10.1016\/j.heliyon.2023.e21776_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.HS9.0000843344.19780.98","article-title":"S112: tisagenlecleucel in pediatric and young adult patients (pts) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-all): final analyses from the ELIANA study","volume":"6","author":"Rives","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.heliyon.2023.e21776_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2021-146393","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel)\u2013An overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2023.e21776_bib17","article-title":"A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma","author":"Ying","year":"2022","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e21776_bib18","article-title":"A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma","author":"Ying","year":"2022","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e21776_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100035","article-title":"Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review","author":"Ahmad","year":"2022","journal-title":"Advances in Cancer Biology - Metastasis"},{"key":"10.1016\/j.heliyon.2023.e21776_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2023.e21776_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00005-020-00599-x","article-title":"The application of CAR-T cells in haematological malignancies","volume":"68","author":"Skorka","year":"2020","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.heliyon.2023.e21776_bib23","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-immunol-032414-112158","article-title":"Early T cell activation: integrating biochemical, structural, and biophysical cues","author":"Malissen","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/ni.2959","article-title":"Integrative biology of T cell activation","author":"Malissen","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib27","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e21776_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"ScFv antibody: principles and clinical application","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2020.03.071","article-title":"Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties","author":"Fujiwara","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e21776_bib30","article-title":"Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005845","article-title":"Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets","author":"Laletin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2023.e21776_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2020.03.071","article-title":"Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties","author":"Fujiwara","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e21776_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2023.e21776_bib35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2023.e21776_bib36","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.3390\/ijms21228620","article-title":"Engineering next-generation CAR-T cells for better toxicity management","volume":"21","author":"Andrea","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e21776_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714822","article-title":"Cell fate reprogramming in the era of cancer immunotherapy","volume":"12","author":"Zimmermannova","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113332","article-title":"Chimeric antigen receptor T-cell therapy: what we expect soon","volume":"23","author":"Martino","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e21776_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.714822","article-title":"Cell fate reprogramming in the era of cancer immunotherapy","author":"Zimmermannova","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12254-020-00577-1","article-title":"AML\u2014is it time to drive a CAR(-T)?","volume":"13","author":"Rudzki","year":"2020","journal-title":"Memo - Magazine of European Medical Oncology"},{"key":"10.1016\/j.heliyon.2023.e21776_bib42","first-page":"1433","article-title":"The growing world of CAR T cell trials: a systematic review, Cancer Immunology","volume":"65","author":"Holzinger","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.heliyon.2023.e21776_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib46","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e21776_bib49","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7150\/jca.2.331","article-title":"Chimeric antigen receptor therapy for B-cell malignancies","volume":"2","author":"Porter","year":"2011","journal-title":"J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2023.e21776_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2023.e21776_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0169-5002(93)90369-9","article-title":"CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas","volume":"10","author":"Waibel","year":"1993","journal-title":"Lung Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.heliyon.2023.e21776_bib57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymthe.2005.08.012","article-title":"Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine\u2013DNA methyltransferase in hematopoietic cells","volume":"13","author":"Schambach","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2023.e21776_bib59","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ymthe.2022.02.012","article-title":"Multipurposing CARs: same engine, different vehicles","volume":"30","author":"Hossian","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2023.e21776_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-021-01161-4","article-title":"Engineered T cells: CAR T cell therapy and beyond","volume":"24","author":"Johnson","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heliyon.2023.e21776_bib61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib62","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e6","article-title":"CAR T cell immunotherapy beyond haematological malignancy","volume":"22","author":"Hupperetz","year":"2022","journal-title":"Immune Netw"},{"key":"10.1016\/j.heliyon.2023.e21776_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2023.e21776_bib64","first-page":"619","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives, Cancer Immunology","volume":"70","author":"Qu","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.heliyon.2023.e21776_bib65","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T\u2010cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2023.e21776_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125423","article-title":"Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients","volume":"134","author":"Schubert","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00885","article-title":"Recognizing and grading CAR T-cell toxicities: an advanced practitioner perspective","volume":"10","author":"Sievers","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth\u2010generation CAR T cells: current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.heliyon.2023.e21776_bib70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib71","article-title":"Cytokine conjugation to enhance T cell therapy","volume":"120","author":"Liu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.heliyon.2023.e21776_bib72","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.heliyon.2023.e21776_bib73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/1735-5362.323911","article-title":"Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer","volume":"16","author":"Rahimmanesh","year":"2021","journal-title":"Res Pharm Sci"},{"key":"10.1016\/j.heliyon.2023.e21776_bib74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00281-022-00962-4","article-title":"Beyond direct killing\u2014novel cellular immunotherapeutic strategies to reshape the tumor microenvironment","volume":"45","author":"Huynh","year":"2023","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-020-06032-3","article-title":"Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy","volume":"186","author":"Luangwattananun","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.heliyon.2023.e21776_bib82","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4088","article-title":"Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma","volume":"39","author":"Fang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3\u2013Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2023.e21776_bib84","first-page":"979","article-title":"[Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)]","volume":"36","author":"Huang","year":"2020","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.heliyon.2023.e21776_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564099","article-title":"Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-hodgkin lymphomas","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib86","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.564099","article-title":"Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-hodgkin lymphomas","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: a scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2023.e21776_bib92","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.heliyon.2023.e21776_bib94","article-title":"The journey of CAR-T therapy in hematological malignancies","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib95","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2023.e21776_bib96","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib97","first-page":"904","article-title":"Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.heliyon.2023.e21776_bib98","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib101","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1039\/D2TB00592A","article-title":"Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy","volume":"10","author":"Balagopal","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.heliyon.2023.e21776_bib102","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2023.e21776_bib103","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2023.e21776_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583716","article-title":"Off-the-Shelf allogeneic T cell therapies for cancer: opportunities and challenges using naturally occurring \u201cuniversal\u201d donor T cells","volume":"11","author":"Perez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001608","article-title":"\u201cOff-the-shelf\u201d allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies","author":"Sinha","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib106","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41591-022-02195-2","article-title":"Off-the-shelf CAR T cells for multiple myeloma","volume":"29","author":"Brudno","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib107","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib109","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/PPO.0000000000000637","article-title":"Emerging challenges to cellular therapy of cancer","volume":"29","author":"Lulla","year":"2023","journal-title":"Cancer J."},{"key":"10.1016\/j.heliyon.2023.e21776_bib110","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib111","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/PPO.0000000000000637","article-title":"Emerging challenges to cellular therapy of cancer","volume":"29","author":"Lulla","year":"2023","journal-title":"Cancer J."},{"key":"10.1016\/j.heliyon.2023.e21776_bib112","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e21776_bib113","series-title":"\u201cOff-the-Shelf\u201d Allogeneic CAR Cell Therapy\u2014Neglected HvG Effect","author":"An","year":"2023"},{"key":"10.1016\/j.heliyon.2023.e21776_bib114","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.heliyon.2023.e21776_bib115","series-title":"Towards a Commercial Process for the Manufacture of Genetically Modified T Cells for Therapy","author":"Kaiser","year":"2015"},{"key":"10.1016\/j.heliyon.2023.e21776_bib116","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/ijms21020515","article-title":"Finding the keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies","volume":"21","author":"Abbott","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e21776_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e21776_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.heliyon.2023.e21776_bib119","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib121","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3087.3087","article-title":"Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","author":"Schuster","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib122","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8515","article-title":"Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel\/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)","author":"Sauter","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2023.e21776_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?","volume":"34","author":"D'Agostino","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2023.e21776_bib125","series-title":"B-Cell Maturation Antigen Is a Promising Target for Adoptive T-Cell Therapy of Multiple Myeloma","author":"Carpenter","year":"2013"},{"key":"10.1016\/j.heliyon.2023.e21776_bib126","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib127","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","author":"Ramos","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib128","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","author":"Wang","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib130","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2023.e21776_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib133","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B-cell ALL","author":"Zanetti","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2023.e21776_bib134","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22\u2013chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib135","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131024","article-title":"Single chain variable fragment linker length regulates CAR biology and T cell efficacy","volume":"134","author":"Singh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib136","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib137","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","author":"Younes","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e21776_bib140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib141","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: results of a phase i study","author":"Fanale","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib143","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd3629","article-title":"Brentuximab vedotin","volume":"11","author":"Younes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2023.e21776_bib144","series-title":"Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference","first-page":"162","author":"Diefenbach","year":"2012"},{"key":"10.1016\/j.heliyon.2023.e21776_bib145","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib146","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib147","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2023.e21776_bib148","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib149","series-title":"Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia","author":"Baskar","year":"2008"},{"key":"10.1016\/j.heliyon.2023.e21776_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2015.06.010","article-title":"Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma","author":"Chang","year":"2015","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib151","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-016-1911-3","article-title":"Expression of ROR1 has prognostic significance in triple negative breast cancer","author":"Chien","year":"2016","journal-title":"Virchows Arch."},{"key":"10.1016\/j.heliyon.2023.e21776_bib152","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2023.e21776_bib153","article-title":"Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K\/AKT\/mTOR signaling pathway in lung adenocarcinoma","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e21776_bib154","series-title":"Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues","author":"Balakrishnan","year":"2017"},{"key":"10.1016\/j.heliyon.2023.e21776_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128151","article-title":"Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations","volume":"10","author":"Deniger","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e21776_bib156","article-title":"Tyrosine kinase ROR1 as a target for anti-cancer therapies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib157","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2023.e21776_bib158","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1186\/2051-1426-2-S3-P3","article-title":"Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model","volume":"2","author":"Berger","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2023.e21776_bib159","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/cancers13030496","article-title":"CD123 is consistently expressed on NPM1-mutated AML cells","volume":"13","author":"Perriello","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2023.e21776_bib160","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib161","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2023.e21776_bib162","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib163","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with cd123-specific CAR T cells: a first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib164","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib165","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"2012","key":"10.1016\/j.heliyon.2023.e21776_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/683065","article-title":"Antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD 33 + acute myeloid leukemia","author":"Dutour","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.heliyon.2023.e21776_bib167","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2023.e21776_bib168","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2023.e21776_bib169","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1730","article-title":"CD33\u2010Targeted therapies: beating the disease or beaten to death?","volume":"61","author":"Maakaron","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib171","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2023.e21776_bib172","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.molonc.2015.10.012","article-title":"CAR T-cell immunotherapy: the path from the by-road to the freeway?","volume":"9","author":"Whilding","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib173","article-title":"CAR T-cell therapy for solid tumors?","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2023.e21776_bib174","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.219.219","article-title":"CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib175","doi-asserted-by":"crossref","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2023.e21776_bib176","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib177","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7003","article-title":"Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL","author":"Park","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib178","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.219.219","article-title":"CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e21776_bib179","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e21776_bib180","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib181","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2023.e21776_bib182","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","article-title":"CAR T cell therapy: inroads to response and resistance","volume":"19","author":"Brown","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib183","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S1470-2045(17)30928-2","article-title":"CAR T-cell therapy in refractory large B-cell lymphoma","volume":"19","author":"Stirrups","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib184","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e21776_bib185","series-title":"Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue while Maintaining Potent Antitumor Activity","author":"Caruso","year":"2015"},{"key":"10.1016\/j.heliyon.2023.e21776_bib186","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/exd.14131","article-title":"Fasten the seat belt: increasing safety of CAR T\u2010cell therapy","volume":"29","author":"Simon","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib187","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.3390\/curroncol30090619","article-title":"Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update","volume":"30","author":"Alsajjan","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib188","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2023.e21776_bib189","first-page":"517","article-title":"CAR T-cell therapy in solid tumors: current review and future perspectives, highlights in science","volume":"54","author":"Zheng","year":"2023","journal-title":"Eng. Technol."},{"key":"10.1016\/j.heliyon.2023.e21776_bib190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.heliyon.2023.e21776_bib191","first-page":"435","article-title":"Management of emergency adverse effects of cart cell therapy in hematologic cancers","author":"Chinthapalli","year":"2023","journal-title":"J. Pharm. Negat. Results"},{"key":"10.1016\/j.heliyon.2023.e21776_bib192","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s44222-023-00031-x","article-title":"Optimizing the manufacturing and antitumour response of CAR T therapy","volume":"1","author":"Liu","year":"2023","journal-title":"Nature Reviews Bioengineering"},{"key":"10.1016\/j.heliyon.2023.e21776_bib193","doi-asserted-by":"crossref","DOI":"10.1080\/15476278.2022.2164159","article-title":"Clinical manufacturing of regulatory T cell products for adoptive cell therapy and strategies to improve therapeutic efficacy","volume":"19","author":"Baron","year":"2023","journal-title":"Organogenesis"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023089843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023089843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:24:14Z","timestamp":1791293054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023089843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":188,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2405844023089843"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21776","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy for hematological malignancies: History, status and promise","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e21776"}}